Low-dosage clonidine (Dixarit) in menopausal flushing

Abstract

Results of an open evaluation of the therapy with low-dosage clonidine (Dixarit) in a series of 20 patients with symptoms of menopausal flushing are presented. Twelve of the 17 patients who completed the 12-week trial noted an improvement in their condition: this improvement was marked in eight patients. The greatest improvement was noted in the perimenopausal group of women whose dosage requirement was 25 microgram three times a day. Postmenopausal women tended to be more refractory to the therapy and required larger dosages for the relief of symptoms.